HIF1A and neoplasm: Recent studies have shown that EVs can alter glycolysis in various tumor cells by targeting HIF-1α, including EVs with ZFPM2-AS1 in liver cancer, EVs with miR-29a-3p in glioma, and EVs with circSHKBP1 in non-small cell lung cancer [79–81].